ALK and neoplasm: Pailler et al. (24) found that “smoking status (≥15 vs. <15 pack-year), number of previous treatment (≥2 vs. <1), number of metastatic sites (≥2 vs. <1), and dynamic change of ALK-copy number gain (CNG) circulating tumor cell counts (stable/increase vs. decrease) were independent predictive factors for PFS”.